Fractures — Pathological / Osteoporosis Fractures

🔍 Definition

A pathological fracture is a fracture that occurs through bone that has been weakened by an underlying disease process — not from the level of trauma that would normally be required to break a healthy bone. Unlike traumatic fractures (coded from the S-chapter), pathological fractures result from conditions such as osteoporosis, neoplastic disease, metabolic bone disorders, or bone infection that compromise structural integrity to the point where minimal or no trauma is sufficient to cause a break.

Osteoporosis is the most common systemic skeletal disease leading to pathological fracture. Defined by the National Osteoporosis Foundation and the International Osteoporosis Foundation as reduced bone mineral density (BMD) and deterioration of bone microarchitecture, osteoporosis results in increased skeletal fragility. A BMD T-score of ≤−2.5 SD below the young adult mean at the femoral neck or lumbar spine constitutes osteoporosis per WHO criteria. A T-score between −1.0 and −2.5 defines osteopenia (low bone mass).

The concept of a fragility fracture (also called a low-energy or low-impact fracture) is central to osteoporosis coding: a fracture resulting from forces equivalent to a fall from standing height or less is presumed to be a fragility fracture, and when osteoporosis is documented, linkage to that underlying condition is appropriate for coding purposes per ICD-10-CM FY2027 Official Guidelines.

Pathological fractures are further classified by etiology: fractures due to osteoporosis (M80.x), fractures due to neoplastic disease (M84.5xx), fractures due to other specified diseases (M84.6xx), stress fractures (M84.3xx), pathological fractures NOS (M84.4xx), and the newer category of atypical femoral fractures associated with bisphosphonate therapy (M84.7xx).

🗂️ Alternative Terminology

Correct code assignment often hinges on recognizing the varied clinical language providers use to describe pathological and osteoporosis-related fractures. The following table maps formal ICD-10-CM terminology to equivalent clinical and lay expressions.

🩺 Signs & Symptoms

Pathological and osteoporotic fractures present differently from traumatic fractures, often with subtle or insidious onset. Clinical recognition guides appropriate documentation and code assignment.

Vertebral Compression Fractures

• Acute or chronic back pain, often thoracic or lumbar, worsened with movement or weight-bearing
• Height loss (>1.5 cm cumulative or >2 cm over time is clinically significant)
• Kyphosis (dowager’s hump / hyperkyphosis) — progressive spinal deformity
• Pain may be absent in up to one-third of cases (silent fractures, incidentally found on imaging)
• Radiculopathy or myelopathy if spinal canal compromise

Hip / Femoral Fractures

• Acute groin, hip, or thigh pain following minimal trauma (ground-level fall)
• Inability to bear weight on affected limb
• Shortened and externally rotated leg (complete displacement)
• Prodromal thigh or groin pain for weeks prior (especially atypical femoral fractures)

Distal Radius / Wrist Fractures

• Wrist pain and deformity after fall on outstretched hand (FOOSH mechanism)
• Dinner-fork deformity (dorsal displacement — Colles type)
• Tenderness at distal radius; limited range of motion

Systemic / General Signs of Underlying Bone Disease

• Low DXA T-score (≤−2.5 at spine or femur = osteoporosis; −1.0 to −2.5 = osteopenia)
• Elevated bone turnover markers (CTX, P1NP) in active remodeling states
• Vertebral fracture assessment (VFA) showing ≥25% vertebral height loss
• Prior fragility fracture (strongest predictor of future fracture)

🧭 Differential Diagnosis

Distinguishing pathological fractures from traumatic fractures — and determining the underlying etiology — is critical for accurate code assignment and appropriate clinical management.

📋 Clinical Indicators

The following indicators should prompt coders and CDI specialists to review documentation for pathological fracture coding opportunities, query needs, or sequencing decisions.

🦴 Anatomy & Pathophysiology

Understanding the anatomical sites and pathophysiological mechanisms of pathological fractures is essential for site-specific code selection and accurate laterality assignment.

Skeletal Sites Most Vulnerable to Osteoporotic Fracture

Osteoporosis preferentially affects sites with high trabecular bone content, which turns over faster and is more sensitive to bone loss:

• Vertebral column (M80.08x) — Thoracic (T4–T12) and lumbar (L1–L4) most common; anterior wedge compression is classic
• Proximal femur (M80.05x) — Femoral neck (intracapsular) and intertrochanteric region; hip fracture carries highest mortality (15–20% 1-year mortality in elderly)
• Distal radius (M80.03x) — Colles fracture pattern; often the first fracture in the fragility fracture sequence
• Pelvis (M80.0Ax) — Sacral and pubic rami insufficiency fractures; often underdiagnosed
• Proximal humerus (M80.02x) — Surgical neck fractures from low-energy shoulder falls
• Ribs and sternum (M80.0Ax, other site) — Can occur from coughing or minor thoracic compression

Pathophysiology of Osteoporosis

Bone is a dynamic tissue undergoing continuous remodeling via the RANK/RANKL/OPG signaling axis. In osteoporosis, there is an imbalance between osteoclast-mediated bone resorption and osteoblast-mediated bone formation (NIH Osteoporosis Overview):

• Postmenopausal osteoporosis (Type I) — Estrogen withdrawal accelerates osteoclast activity; predominantly affects trabecular bone; accounts for most early postmenopausal fractures at wrist and vertebrae
• Age-related osteoporosis (Type II) — Affects both cortical and trabecular bone; occurs in men and women after age 70; associated with hip and vertebral fractures
• Secondary osteoporosis — Caused by glucocorticoid excess (endogenous or exogenous), hypogonadism, malabsorption, renal disease, hyperthyroidism, immobilization

Atypical Femoral Fractures (M84.7xx)

A distinct subtype associated with long-term bisphosphonate therapy (≥3–5 years) or denosumab. Characterized by:

• Location at subtrochanteric region or femoral shaft (NOT neck or intertrochanteric)
• Transverse or short oblique fracture pattern on imaging
• Cortical thickening at the lateral cortex (“beaking” or “dreaded black line”)
• Minimal or no trauma history
• Bilateral occurrence in up to 30% of cases — assess contralateral femur

Pathological Fractures in Neoplastic Disease

Metastatic bone disease disrupts normal bone remodeling. Lytic metastases (breast, kidney, thyroid, multiple myeloma) destroy cortical and trabecular bone integrity, leading to pathological fracture through the weakened bone. Blastic lesions (prostate) can also fracture due to disorganized, brittle bone structure. The Mirels scoring system is used clinically to assess fracture risk in metastatic bone disease.

💊 Medication Impact / Treatment

Medications play a dual role in pathological fracture coding: as treatments that must be documented to support clinical necessity, and as causative agents that can themselves cause fractures (adverse effects). CDI specialists must recognize both contexts.

Osteoporosis Pharmacotherapy (Fracture Prevention)

• Bisphosphonates — Alendronate (Fosamax), risedronate (Actonel), ibandronate (Boniva), zoledronic acid (Reclast IV, J3489). Antiresorptive; reduce vertebral fracture risk 40–70%, hip fracture risk 40–50%. Long-term use (>5 years) associated with atypical femoral fracture risk (M84.7xx) and osteonecrosis of the jaw
• Denosumab (Prolia, J0897) — RANKL inhibitor; subcutaneous injection every 6 months. Reduces vertebral and hip fracture risk similarly to bisphosphonates. Rebound fracture risk upon discontinuation must be documented and transitioned appropriately
• Teriparatide (Forteo, J3110) / Abaloparatide (Tymlos) — Anabolic agents; parathyroid hormone analogues that stimulate new bone formation; used for severe osteoporosis or treatment failures. Significantly reduces vertebral and nonvertebral fracture risk
• Romosozumab (Evenity) — Dual anabolic/antiresorptive; sclerostin inhibitor; used in high-risk patients; 12-month course followed by antiresorptive therapy
• Raloxifene (Evista) — SERM; reduces vertebral but not hip fracture risk; used in postmenopausal women; also reduces breast cancer risk
• Calcium + Vitamin D supplementation — Adjunctive to all pharmacotherapy; inadequate vitamin D documented should be coded separately (E55.x)

Medications That Cause or Worsen Bone Loss (Document for Adverse Effect/Underdosing Coding)

• Glucocorticoids (prednisone, dexamethasone, methylprednisolone) — Most common cause of drug-induced osteoporosis; >5 mg/day prednisone equivalent for >3 months significantly increases fracture risk; requires adverse effect code from T38.0x series if osteoporosis/fracture is documented as related
• Aromatase inhibitors (anastrozole, letrozole) — Used in breast cancer; accelerate bone loss; fracture risk documented with M80.80xx or M84.6xx
• Androgen deprivation therapy (ADT) — Prostate cancer treatment; accelerates bone loss
• Proton pump inhibitors (PPIs) — Long-term use associated with modest increased fracture risk (reduced calcium absorption)
• Loop diuretics, anticonvulsants, heparin, SSRIs — Secondary contributors to bone loss

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.

← Back to All Clinical Documentation Guides

📘 ICD-10-CM Guidelines

Official guidance for pathological and osteoporosis fracture coding is found in ICD-10-CM FY2027 Official Guidelines for Coding and Reporting, Section I.C.13 (Diseases of the Musculoskeletal System and Connective Tissue).

Guideline I.C.13.d — Osteoporosis Without Pathological Fracture and Osteoporosis With Current Pathological Fracture

Category M80 (Osteoporosis with current pathological fracture) is used when osteoporosis is the underlying cause of the fracture. The fracture must be documented as pathological or due to osteoporosis — not as a traumatic fracture. The guidelines distinguish:

• M80.0xx — Age-related (postmenopausal/senile) osteoporosis with current pathological fracture
• M80.80xx — Other osteoporosis with current pathological fracture (secondary osteoporosis: glucocorticoid-induced, disuse, post-surgical, malabsorption)

Guideline I.C.13.c — Pathologic Fractures: 7th Character Requirements

All fracture codes in categories M80 and M84 require a 7th character specifying the episode of care:

• A — Initial encounter for fracture (active fracture treatment; includes the entire period of active treatment regardless of setting)
• D — Subsequent encounter for fracture with routine healing
• G — Subsequent encounter for fracture with delayed healing
• K — Subsequent encounter for fracture with nonunion
• P — Subsequent encounter for fracture with malunion
• S — Sequela

Critical rule: For pathological fractures, the 7th character “A” is used for the initial encounter — but also for all subsequent visits while the fracture is being actively treated, even if seen by a different provider or in a different care setting. The 7th character “D” is used once active fracture treatment has concluded and the patient is receiving routine aftercare. “A” and “D” are both HCC-qualifying for categories M80 and M84.5/6/7.

Guideline I.C.13.c — Sequencing: Pathological Fracture vs. Underlying Condition

For osteoporotic fractures (M80.x), the fracture code itself is the principal/first-listed diagnosis — the osteoporosis etiology is built into the M80.x code (it is not coded separately via M81.x). For pathological fractures due to neoplasm (M84.5xx), the neoplasm is sequenced first, followed by the M84.5xx code. Similarly, for M84.6xx (fracture in other disease), the underlying disease is sequenced first.

Guideline I.C.13.d — Osteoporosis Without Fracture (M81.x)

Category M81 codes osteoporosis when NO current pathological fracture is present. M81.0 (age-related osteoporosis without fracture) and M81.8 (other osteoporosis without fracture) are NOT HCC-mapping codes but remain clinically important for chronic disease documentation and risk assessment. Z87.310 (personal history of osteoporotic fracture) should be assigned when a prior fracture has healed.

Guideline I.C.13.d.2 — Osteoporosis With Current Pathological Fracture / Minor Trauma Rule

Per guidelines, when a patient has documented osteoporosis AND sustains a fracture from a low-energy mechanism (fall from standing height, minor trauma), the fracture may be presumed to be related to the osteoporosis and coded with M80.x — even if the provider does not explicitly use the term “pathological fracture.” However, if the provider explicitly documents that the fracture is traumatic (unrelated to osteoporosis), S-chapter codes should be used.

Coding Note — Atypical Femoral Fracture (M84.7xx) FY2024+

Category M84.7 (Atypical femoral fracture) was introduced in FY2024 and remains active in FY2027. These codes require documentation of both the atypical fracture characteristics and the bisphosphonate/antiresorptive drug relationship. Assign the appropriate documented drug adverse-effect code as an additional code. The appropriate 7th character (A, D, G, K, P, S) is required.

🔢 ICD-10-CM Code Set (Tabular)

M80.x — Osteoporosis WITH Current Pathological Fracture

These codes require a 7th character (A/D/G/K/P/S) and site-specific 5th/6th characters for laterality where applicable. (FY2027 ICD-10-CM Tabular)

M81.x — Osteoporosis WITHOUT Current Pathological Fracture

M84.3xx — Stress Fractures

M84.4xx — Pathological Fractures NOS (Not Elsewhere Classified)

M84.5xx — Pathological Fracture in Neoplastic Disease

M84.6xx — Pathological Fracture in Other Disease

M84.7xx — Atypical Femoral Fracture (FY2024 New Category, Active FY2027)

Additional Related Codes

🔎 Indexing

The ICD-10-CM Alphabetic Index is the primary entry point for code selection. The following table maps common clinical expressions to their index pathways and resulting codes.

🏥 CPT

The following CPT codes are most frequently reported in the surgical and diagnostic management of pathological and osteoporotic fractures. Verify all codes against the AMA CPT 2027 codebook and payer policy for the date of service.

🧾 HCPCS

HCPCS Level II codes are used primarily for DME, drugs administered in the office or outpatient infusion setting, and supplies. The following codes are relevant to osteoporosis and pathological fracture management.

📚 AHA Coding Clinic

The following AHA Coding Clinic advisories are directly relevant to pathological and osteoporosis fracture coding. CDI specialists and coders should be familiar with these authoritative interpretations.

💰 HCC / Risk Adjustment

Under the 2024 CMS-HCC model (V28), which CMS continues to use for CY 2027 non-PACE Medicare Advantage risk scores, pathological fractures map to HCC 170 (Pathological Fracture) and HCC 171 (Pathological Fracture — Vertebral) depending on site and etiology. Accurate RAF capture requires encounter documentation and the correct ICD-10-CM 7th character for the treatment phase.

HCC Capture Best Practices

• Use 7th character “A” while the patient is receiving active fracture treatment; use “D” for routine healing after active treatment has concluded; do not select a 7th character solely to influence HCC capture
• M81.x (osteoporosis without fracture) does not map to any HCC — clinicians should document active fractures when present
• Pathological fractures in neoplastic disease (M84.5xx) carry dual HCC impact — the fracture HCC (170/171) PLUS the applicable neoplasm HCC
• Document fracture at every encounter during active treatment — HCC v28 is a prospective annual model requiring documentation in the measurement year
• Subsequent encounters with “D” represent routine healing after active treatment has concluded; verify current CMS-HCC mappings for whether the specific code/7th character maps to HCC 170/171

✍️ CDI Query Templates

The following query templates are designed to be AHIMA/ACDIS-compliant: non-leading, multiple-choice where appropriate, and focused on clinical clarification. All queries should be preceded by clinical evidence documentation (e.g., citing DXA results, imaging findings, drug history).

🧑‍⚕️ Treatments (Clinical)

Understanding the clinical treatment pathways for pathological and osteoporotic fractures supports documentation completeness, procedure code selection, and MS-DRG optimization.

Vertebral Compression Fractures

• Conservative management — Pain control (analgesics, calcitonin nasal spray for acute pain), activity modification, back bracing (TLSO), physical therapy, calcium/vitamin D supplementation
• Vertebroplasty (CPT 22510/22511; +22512 additional level) — Percutaneous cement injection into a fractured vertebral body; 22510 reports a cervicothoracic level, 22511 reports a lumbosacral level, and +22512 reports each additional cervicothoracic or lumbosacral level; indicated for acute/subacute VCF with persistent pain not responding to conservative measures
• Vertebral augmentation with cavity creation (eg, kyphoplasty; CPT 22513/22514; +22515 additional level) — Cavity creation using a mechanical device followed by cement injection; 22513 reports a thoracic level, 22514 reports a lumbar/sacral level, and +22515 reports each additional thoracic, lumbar, or sacral level; may attempt height restoration and kyphosis reduction
• Surgical fusion — Reserved for unstable fractures with neurological compromise; posterior spinal instrumentation (CPT 22800 series)

Hip / Femoral Fractures

• Femoral neck fractures (displaced) — Hemiarthroplasty or total hip arthroplasty (CPT 27125/27130); early surgery within 24–48 hours reduces mortality
• Femoral neck (non-displaced) — Internal fixation with cannulated screws (CPT 27235)
• Intertrochanteric fractures — Cephalomedullary nail (IMHS) is gold standard (CPT 27245); sliding hip screw (CPT 27244) for stable patterns
• Atypical femoral fractures (M84.7xx) — Prophylactic nailing with intramedullary nail for contralateral side if significant cortical thickening; surgical fixation for completed fracture (CPT 27506); bisphosphonate discontinuation; teriparatide may accelerate healing

Distal Radius Fractures

• Non-displaced / minimally displaced — Closed reduction and cast immobilization; no CPT surgical code
• Displaced / unstable — ORIF with volar locking plate (CPT 25607–25609); percutaneous pinning (CPT 25600–25606)

Inpatient MS-DRG Impact

Osteoporotic hip fracture admissions typically route to MS-DRG 480–482 (Hip & Femur Procedures Except Major Joint) depending on MCC/CC/no CC. Vertebral fractures treated with kyphoplasty/vertebroplasty may route to MS-DRG 459–460 (Spinal Fusion) or 487–489 (Back & Neck Procedures) depending on procedure performed. Pathological fractures in neoplastic disease will significantly elevate DRG complexity through the neoplasm diagnoses.

Systemic Osteoporosis Treatment (Fracture Secondary Prevention)

Post-fracture initiation of osteoporosis pharmacotherapy remains dramatically underutilized — the “osteoporosis treatment gap.” Documentation of treatment initiation or planned initiation during fracture hospitalization is a quality measure (NQF #0053) and should be captured in the discharge summary. Assign Z79.83 (long-term bisphosphonate use) or Z79.890 (HRT) when applicable.

🎓 Patient Education / Summary

What Are Pathological / Osteoporosis Fractures? (Plain Language)

A pathological fracture happens when a bone breaks because it has become weak — not because of a hard hit or major accident. In osteoporosis, bones lose density over time, becoming thinner and more fragile. Even a minor fall, a sneeze, or just bending forward can cause a bone to break in someone with severe osteoporosis. The spine (vertebrae), hip, and wrist are the most common places where these fractures happen.

Key Patient Education Points (CDI Relevance)

• Report ALL falls — Even ground-level falls should be reported to the care team, no matter how minor they seem. A fall from standing height can cause a serious fracture in someone with osteoporosis.
• Osteoporosis is treatable — Medications such as bisphosphonates, denosumab, and teriparatide can significantly reduce future fracture risk. Adherence to prescribed medications is critical; stopping or delaying denosumab without planned follow-on therapy can increase fracture risk, including multiple vertebral fractures.
• Bone density testing (DXA) — Women over 65 and men over 70 should have bone density testing. Patients with risk factors (prior fracture, steroid use, family history) may need testing earlier. Results (T-scores) guide treatment decisions.
• Vertebral fractures may be silent — Some spine fractures cause no pain and are found incidentally. Height loss of more than 1.5 cm should prompt imaging evaluation.
• Fall prevention — Home safety modifications (remove trip hazards, install grab bars), exercise programs focused on balance and strength (tai chi, weight-bearing activity), vision and hearing correction, and medication review to minimize fall-risk medications.
• Calcium and Vitamin D — Adequate dietary calcium (1000–1200 mg/day) and vitamin D (800–1000 IU/day) are foundations of bone health. Deficiency should be documented and treated.

Common Patient Misunderstandings That Create Documentation Gaps

• “I just fell — it’s not like I have a disease.” — This misunderstanding leads to traumatic fracture coding when the correct code is M80.x (pathological). The care team must document the osteoporosis-fracture relationship.
• “My fracture healed, so my osteoporosis is better.” — Healed fracture (Z87.310) does not mean osteoporosis is resolved. The underlying condition requires ongoing treatment and documentation at each encounter.
• “I stopped taking my bone medication because my doctor said I could take a drug holiday.” — Bisphosphonate drug holidays should be documented clearly; rebound fracture risk with denosumab discontinuation should be explicitly addressed in the record.

Quality Measure Intersections

• HEDIS OMW — Osteoporosis Management in Women Who Had a Fracture: women ages 67–85 with a qualifying fracture should have either a bone mineral density (BMD) test or a prescription/drug therapy for osteoporosis within 180 days (6 months) after the fracture. Document BMD testing, therapy administered, or medication filled when available.
• HEDIS OSW — Osteoporosis screening in older women. Document DXA results and dates.
• CMS Star Rating — Osteoporosis drug treatment following a fracture is a Medicare Part D Star measure. Documentation of prescribed therapy supports quality scoring.
• FRAX risk score — The FRAX tool (WHO fracture risk assessment) provides 10-year fracture probability; document the score when used to guide treatment decisions — it supports medical necessity for pharmacotherapy initiation.

About this Guide

This Clinical Documentation Guide is published by CCO Academy and is intended for credentialed coding, CDI, and clinical documentation professionals. Content is updated for FY2027 ICD-10-CM (effective October 1, 2026) and CPT/HCPCS 2027 where noted. All code assignments should be verified against the official ICD-10-CM Tabular List, AHA Coding Clinic, CPT/HCPCS guidance, and applicable payer-specific policies. This guide does not constitute legal, medical, or compliance advice.

Last reviewed: October 2026 · Next scheduled review: April 2027